Transcriptional positive coactivator 4 (PC4) is a multifunctional nuclear protein that has important roles in DNA transcription, replication, repair and heterochromatinization. However, the role of PC4 in cancer remains to be clarified. Several studies propose that PC4 may act as a putative tumor suppressor. Here, we demonstrate for the first time that PC4 may represent a potential therapeutic target in non-small cell lung cancer (NSCLC). PC4 protein expression is significantly upregulated in NSCLC carcinoma tissues compared with their adjacent noncancerous counterparts as shown by immunohistochemical staining and western blotting in 104 pairs of formalin-fixed human NSCLC specimens and 6 fresh NSCLC samples. Knockdown of PC4 expression by sequence-specific small interfering RNA (siRNA) in human NSCLC cells (A549, H460 and H358) significantly inhibits the growth of cancer cells by the induction of cell cycle arrest and the increase of cell apoptosis in vitro. Interrupting the PC4 signaling pathway by injection of the PC4 siRNA liposome complex produced an effective regression of pre-established A549 cell xenografts in mice through growth inhibition and increased apoptosis. These results indicated that PC4 could be an attractive new therapeutic target for the treatment of NSCLC.
INTRODUCTION
Lung cancer is the leading cause of cancer-related deaths. Approximately 1.6 million new cases are diagnosed 1 and nearly 1.4 million patients die of lung cancer worldwide each year. 2 Nonsmall cell lung cancer (NSCLC) accounts for B85% of all lung cancers. And about 40% of NSCLC are often in an advanced stage when diagnosing. 3 Moreover, although the overall 5-year survival rate of NSCLC patients is only 10-15%, that of patients with stage IA NSCLC exceeds 80%. 4 Thus, the early diagnosis and therapy of NSCLC is extremely necessary. As a promising approach for NSCLC treatment, molecular targeted therapy has been studied and several targeted agents have been explored recently, 5 including the antagonists of epidermal growth factor receptor 6 and vascular endothelial growth factor, 7 inhibitors of anaplastic lymphoma kinase 8 and others. 1 However, there is still a need to identify new specific and efficient targeting molecules to provide multipathways for future NSCLC therapy.
As a highly abundant nuclear protein, human positive coactivator 4 (PC4) has been reported to be involved in various cellular processes including DNA transcription, replication, repair and heterochromatinization. [9] [10] [11] [12] [13] It is a member of chromatinassociated protein superfamily and has a critical role in chromatin organization. 14 Studies have reported that PC4 could activate p53 activity as well as a responsive gene of p53. [15] [16] [17] PC4 was also shown to restore AP-2 activity and suppress ras-induced transformation. 18 Through interacting with human DNA repair protein XPG, PC4 could prevent mutagenesis and killing by oxidative DNA damage. 19 These findings suggest that PC4 may act as a putative tumor suppressor. However, in contrast to the proposed statement as a tumor suppressor, PC4 has been recently found to show an upregulated level in several kinds of cancer. [20] [21] [22] [23] [24] Moreover, our previous work indicated that overexpression of PC4 in a population of normal dermal multipotent fibroblasts results in the tumorigenic transformation of the cells, indicating the role of PC4 in tumor development and progression. 20 This prompted us to further study the significance of PC4 in cancer therapy. Here, we report for the first time the role of PC4 as a potential novel therapeutic target for NSCLC.
MATERIALS AND METHODS

Cell lines and tissue samples
The human lung fibroblast cell line HFL1, SCLC cell line H446 and NSCLC cell lines H1299, H358, SK-MES-1, A549 and H460 were obtained from the American Type Culture Collection (Manassas, VA) and maintained as recommended. All cells were grown in appropriate medium with 10% fetal calf serum and maintained at 37 1C with 5% CO 2 . A total of 104 paraffinembedded lung cancer samples of which 74 were with paired adjacent tissues and 30 were unpaired tumor tissues, as well as 6 frozened lung cancer samples with paired adjacent tissues were obtained through the affiliated hospitals of our university. All lung cancer patients were diagnosed by at least two experienced pathologists independently. The study was approved by the Ethics Committee of the Third Military Medical University.
Immunohistochemistry
All tissue sections (4 mm) were dewaxed, rehydrated and incubated in 3% (v/v) hydrogen peroxide in deionized water for 15 min, then added blocking normal goat serum and followed by incubation at 4 1C overnight with human PC4 antibody (1 : 500; Santa Cruz Biotechnology, Santa Cruz, CA). 1 Sections were then incubated with biotinylated second antibody and the streptavidin-biotin peroxidase complex (ZSGB-BIO, Beijing, China). After incubation in a 3, 3'-diaminobenzidine kit (ZSFB-BIO), slides were lightly counterstained with hematoxylin and mounted. Expression of PC4 was evaluated by staining intensity and the percentage of positive cells in a specimen as described previously. 25, 26 A total 'staining score' of 0-12 was calculated and graded as negative (score 0-1), weak (score 2-4), moderate (score [5] [6] [7] [8] and strong (score 9-12).
RNA interference assay
The siRNA sequences targeting human PC4 gene were chemically synthesized as reported previously: 14 
Cell growth assay
Cell proliferation assay was carried with the Cell Couting Kit-8 (CCK-8, Dojindo, Kumamoto, Japan) according to the manufacturer's instruction. Twenty-four hours after transfection, cells were harvested, plated in 96-well plates (2000 cells per well with 100 ml growth medium) and grown in a 5% CO 2 incubator at 37 1C. Cell viability was determined every 24 h at 450 nm by a Model 680 microplate reader (Bio-Rad, Hercules, CA).
Cell cycle assay
Cell cycle was detected by a BD FACS Calibur flow cytometer and Cell Quest software (Becton Dickinson, Franklin Lakes, CA) following the manufacturer's protocols. Forty-eight hours after transfection, both culture media and cells were collected, centrifuged and fixed with 70% ethanol, and then the DNA content was analyzed by flow cytometry.
Cell apoptosis assay
Cell apoptosis was detected by the Annexin V-fluorescein isothiocyanate Apoptosis Detection Kit (Beyotime, Jiangsu, China). Forty-eight hours after transfection, both culture media and cells were collected, centrifuged, washed with phosphate-buffered saline and counted with an electronic cytometer (Beckman Coulter, Miami, FL). Approximately 1.0 Â 10 5 cells were resuspended in 190 ml Annexin V-fluorescein isothiocyanate-binding buffer, and then 5 ml Annexin V-fluorescein isothiocyanate and 5 ml propidium iodide were added for 10-min incubation away from light at room temperature. The samples were detected and analyzed by flow cytometry.
Western blotting
Total proteins were extracted from NSCLC tissues and cell lines using T-PER (Pierce, Rockford, IL) following the manufacturer's instructions. Fifty microgram of total proteins were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and blotted onto polyvinylidene difluoride membranes (Millipore, Bedford, MA). Primary antibodies against PC4 (1 : 500), PCNA (1 : 1000), p21(1 : 500), cyclinD1(1 : 400), casepase-3(1 : 250), poly-(ADP-ribose)polymerase(1 : 1000) and glyceraldehyde-3-phosphate dehydrogenase (1 : 5000) were used at 4 1C overnight. Washed with 0.1% (v/v) phosphate-buffered saline-Tween three times for 10 min each, the membranes were incubated with horseradish peroxidase-labeled goat anti-rabbit or anti-mouse second antibody (1 : 2000; Santa Cruz Biotechnology) for 1 h at 37 1C. After washing, BeyoECL Plus (Beyotime) was used for the enhanced chemiluminescence immunodetection.
Assessment of mitochondrial membrane potential
For measurement of the mitochondrial membrane potential (Dcm), different groups of cells at a density of 8 Â 10 5 ml À 1 were stained with Rh123 (10 mM, Invitrogen) for 30 min at 37 1C, and analyzed using flow cytometry. The excitation and emission wavelengths were 488 and 525 nm, respectively.
Intracellular reactive oxygen species concentration
Different groups of cells at a density of 8 Â 10 5 ml À 1 were stained for intracellular reactive oxygen species using 1 mM DCF-DA (Beyotime) for 20 min and analyzed using flow cytometry. The excitation and emission wavelengths were 488 nm (blue) and 525 nm (green), respectively.
Intracellular ATP concentration
The intracellular ATP concentration of different groups was measured using an ATP assay kit (Beyotime) according to the manufacturer's protocol. Briefly, different groups of A549 cells were lysed in lysis buffer and centrifuged. Supernatants (200 ml) were collected and 10 ml were mixed with 100 ml luciferin-luciferase complex. The luminescent signal was then measured using a luminometer (Berthold, Pforzheim, Germany). Three concentrations of ATP (0.1, 1 and 10 mM) were used to calculate a standard curve to calibrate the signal of the extracts. The protein concentrations of different samples were measured using a protein assay kit (Beyotime).
Tumor model in nude mice
Tumor model in vivo was established using 4-week-old male athymic nude mice in specific pathogen-free room following previously reported protocols. 27 In brief, three groups of six mice each were inoculated subcutaneously with 5 Â 10 6 A549 cells in 200 ml of phosphate-buffered saline at a single dorsal site. After 2 weeks, the tumor-bearing mice were treated with an intratumoral injection every 2 days for 2 weeks as follows: the group 'control', 20 ml of sterilized 0.9% (w/v) NaCl solution for each mouse; group 'NC', 0.8 mg of nonspecific scramble siRNA mixed with 19.2 ml of Lipofectamine2000 for each mouse; and group 'si', 0.8 mg of PC4 specific siRNA mixed with 19.2 ml of Lipofectamine2000 for each mouse. Tumor size was measured with sliding calipers in three dimensions every another day for 26 days and calculated according to the formula: volume (mm 3 ) ¼ (smallest diameter width 2 Â largest diameter length)/2. 28 When mice were euthanized, tumors were excised and weighed with an electronic balance, then fixed and stained with hematoxylin and eosin for morphological examination. Terminal transferase dUTP nick-end labeling staining was carried out using the In Situ Cell Death Detection Kit (Roche, Mannheim, Germany). Apoptotic cells on each section were scored as described above.
Statistical analysis
Data were expressed as mean±s.d. and statistical analysis was carried with w 2 test and one-way analysis of variance using the SPSS 13.0 software package (SPSS, Chicago, IL). Statistical differences were accepted at Po0.05. Each experiment was performed in triplicate.
RESULTS
Upregulation of PC4 protein expression in human NSCLC
To investigate the clinicopathological significance of PC4, we evaluated PC4 expression by immunohistochemistry in 104 pairs of human NSCLC and adjacent noncancerous counterparts. From the clinical data, we could conclude that PC4 expression was more frequently in carcinomas (74.04%) than adjacent tissues (49%, Po0.01; Figure 1a ). By average staining score, adjacent noncancerous tissues had significantly lower PC4 level than tumor tissues (1.13±0.9 versus 4.32±1.81, Po0.01, Figure 1b) . To further confirm these observations, six fresh pairs of NSCLC samples and adjacent noncancerous tissues were collected and subjected to western blotting, which showed that PC4 expression in NSCLC tumor samples was higher than that in their adjacent noncancerous tissues (Figure 1c) , consistent with immunohistochemical staining.
Downregulation of PC4 inhibits proliferation of NSCLC cells
The expression of PC4 was also measured by western blotting in the human normal lung fibroblast cell line HFL1 and the human lung cancer cell lines H1299, H358, H446, SK-MES-1, A549 and H460. As shown in Figure 2a , H358, A549 and H460 cells expressed relatively higher levels of PC4, whereas HFL1,
H1299, H446
and SK-MES-1 cells exhibited a lower level. Based on this result, we selected A549, H460 and H358 cells with higher PC4 level for further research. The expression of PC4 in the selected cell lines was evaluated 48 h after siRNA interference. Our results showed that PC4 was effectively downregulated in A549, H460 and H358 cells treated with the PC4 siRNA (group 'si'), compared with without treatment (group 'control') and the scramble siRNA (group 'NC'; Figure 2b ). In addition, we observed that the growth of cancer cells was markedly influenced and suspension cells appeared obviously 48 h after transfection in the group 'si' alone, but with no effect in the group 'NC' and 'control' (Figure 2c ). As followed, we carried out cell growth assays of A549, H460 and H358 cells using CCK-8. As shown in Figure 3a , OD values in the group 'si' were significantly lower than that in the group 'control' and 'NC' (Po0.01, A549 on 2-4 days, H460 on 3-5 days and H358 on 4-6 days), indicating that knockdown of PC4 in A549, H460 and H358 cells could induce cell growth inhibition.
Downregulation of PC4 induces cell cycle arrest of NSCLC cells To determine the potential mechanism of PC4 on cell growth inhibition, we measured the cell cycle distribution of transfected A549, H460 and H358 cells, respectively. The results (Figure 3b) showed that 48 h after transfection, the G1 cell population in the group 'si' was larger than that in the group 'control' (Po0.05) and group 'NC' (Po0.05), whereas the S cell population in the group 'si' was smaller than that in the group 'control' (Po0.05) and group 'NC' (Po0.05). However, there was no significant difference in the phase G2. Similar results were also observed in H460 and H358 cells. These data suggest that downregulation of PC4 expression in A549, H460 and H358 cells induces G1-phase arrest. 
Downregulation of PC4 induces apoptosis of NSCLC cells
In addition to cell cycle arrest, we continued to detect the cellular apoptosis of transfected A549, H460 and H358 cells (Figure 3c ). Our results (Figure 3d) showed that 48 h after transfection, the numbers of apoptotic cells in the group 'si' were all larger than that in the group 'NC' (Po0.05) and group 'control' (Po0.05), whereas the numbers of normal cells in the group 'si' were all smaller than that in the group 'control' (Po0.05) and group 'NC' (Po0.05). The results suggest PC4 siRNA interference also could induce apoptosis of A549, H460 and H358 cells.
Molecular alterations in A549 cells by PC4 knockdown
Along with PC4 knockdown in A549 cells, we observed a decrease of PCNA and cyclin D1, an increase of p21, the activation of caspase-3 and the cleavage of poly-(ADP-ribose)polymerase, with similar levels of glyceraldehyde-3-phosphate dehydrogenase as controls (Figure 4a ). These data indicate that downregulation of PC4 could induce cell cycle arrest and apoptosis in A549 cells and lead to significant growth inhibition of cancer cells. As tumor cells exhibits high metabolic activities, 29 we further detected the changes of mitochondrial functions caused by PC4 knockdown. 
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After treated by PC4 siRNA, A549 cells in the group 'si' showed lower ATP level (Figure 4b ), lower reactive oxygen species production ( Figure 4c ) and lower Dcm (Figure 4d) , suggesting a downregulation of metabolic activities to further verify the behavior change of cancer cells. However, whether PC4 is a cause for this change in cancer cells remains to be clarified.
Downregulation of PC4 inhibits tumorigenicity of A549 cells in vivo
Through establishing A549 tumor model in nude mice, we examined the in vivo antitumor ability of PC4 siRNA. As PC4 knockdown induced in vitro the most obvious apoptosis (Figures  3c-d) , we chose A549 cells as the model for animal experiments. We observed smaller xenografts in the group 'si' than that in the group 'control' and 'NC' (Po0.05 on 22-26 d; Figure 5a ). In addition, the mean tumor weight of the group 'si' at the endpoint of killing was smaller than that of the group 'control' (Po0.05) and group 'NC' (Po0.05; Figure 5b) . Under light microscopy, we further observed conspicuously reduced blood vessel formation and substantial tumor necrosis and increasing positive apoptotic cells only in the group treated with PC4 siRNA (Figure 5c) . Moreover, as shown in Figure 5d , the average score of terminal transferase dUTP nick-end labeling staining in tumors treated with PC4 siRNA was significantly higher than that in tumors treated with scramble siRNA (Po0.01) or sterilized 0.9% (w/v) NaCl solution (Po0.01). These results further indicate that downregulation of PC4 expression induces tumorigenicity inhibition and apoptosis promotion of A549 cells in vivo.
DISCUSSION NSCLC is the most common cause of cancer-related death among males and second only to breast cancer among females worldwide. 30 It develops through a multistep process from normal lung epithelial cells to frank malignancy involved in the accumulation of complicate genetic and epigenetic abnormalities, including DNA sequence alterations, copy number changes and aberrant promoter hypermethylation.
31
Although platinum-based combination chemotherapy is the first-line therapy of choice, the prognosis for patients with advanced NSCLC remains poor. 32 Frequent multidrug resistance to chemotherapeutic agents is a main barrier to possibly curative treatments for advanced NSCLC. 33 It is therefore required new therapeutic agents that selectively target altered signaling pathways.
Gene expression is largely regulated at the transcription level and tightly associated with most cellular functions. It is, therefore, not surprising that many cancer gene products are indeed functioning as transcription factors, such as growth factors, nuclear hormone receptors, tumor suppressor proteins, onco-proteins and some protein kinases 34, 35 In fact, many cancer-related proteins were originally identified and characterized as transcription factors that have important roles in regulating transcription activation of essential cellular genes. In this work, we have shown that a universal transcription coactivator, PC4, may act as a potential biomarker and therapeutic target in the therapy of NSCLC. Our results clearly showed that the over expression of PC4 protein is detected in a significant population of the lung cancer patients. In addition to its role as a putative tumor suppressor in normal cellular growth, some other studies also suggest that PC4 may also be involved in the tumorigenesis, probably through the activation or synergizing of other genes required in the pathogenesis of cancer. [20] [21] [22] [23] [24] A possible involvement of PC4 in oncogenesis in a chemically induced rat pancreatic B-cell tumor was first observed in 1984. 21 Using a general cDNA screen method, Soma et al. were able to identify a clone encoding for 119 amino-acid residues that showed a clearly positive reaction only with a probe derived from rat pancreatic B-cell tumor, but not the probe derived from normal islet B cells. Sequence analysis indicated that the deduced aminoacid sequence is identical to the PC4, but missing the N-terminal eight residues. As DNA chip and microarray technologies have become more advanced, several groups reported that PC4 expression was upregulated in different tumor tissues or cell lines. Comparative genomic hybridization studies indicated that PC4 was one of the three genes that showed amplification and consequent over expression in the NSCLC cell lines. 22 Gene expression profiling indentified that the expression of PC4 in invasive intraductal papillary mucinous neoplasm of the pancreas was increased 28-fold compared with normal pancreatic epithelium. 23 Statistical analysis of gene expression data from primary colorectal carcinomas, liver metastases and carcinomatoses identified PC4 as one of the top 20 genes upregulated in carcinomatoses. 24 Our recent work also indicated that exogenous overexpression of PC4 could induce the transformation of a population of normal dermal multipotent fibroblasts to acquire malignant characteristics of anchorindependent growth in vitro and tumorigenity in nude mice. 20 In our present study, we have investigated the potential role of PC4 in NSCLC and suggested that PC4 might have an important function as a therapeutic target for NSCLC. We first investigated the expression of PC4 in 104 cases and 6 fresh samples of NSCLC and adjacent noncancerous tissues, and the results showed that PC4 expression was significantly increased in NSCLC specimens compared with their adjacent noncancerous tissues. We next collected five human NSCLC cell lines and selected three from that, which expressed high levels of PC4 proteins. Then, we transfected the PC4 sequence-specific siRNA with Lipofectamine2000 into the selected NSCLC cells in vitro or transplantation tumors of A549 cells in vivo, with the aim of determining whether altering PC4 levels could modulate the proliferation and growth of NSCLC cells, and the results indicated that downregulation of PC4 markedly inhibited NSCLC cell proliferation in vitro, or A549 cell tumorigenicity in an animal model. The therapeutic effect by targeting PC4 in NSCLC is proposed through several possible mechanisms ( Figure 6 ): first, downregulation of PC4 expression led to G1-phase arrest and S-phase decrease in A549, H460 and H358 cells. Furthermore, downregulation of PC4 was associated with a decrease of PCNA, cyclin D1, and an increase of p21, suggesting that PC4 might have a part in the carcinogenesis of NSCLC related to cell proliferation and cell cycle. This work suggested that PC4 might delay the progression of cell cycle from G1 to S phase through the suppression of p21 expression, which is essential for arresting cells at the G1/S checkpoint. Second, PC4 sequence-specific siRNA could induce significant cell apoptosis in NSCLC cells in vitro, also lead to apoptosis of A549 cell xenografts in vivo. Moreover, with the reduction of PC4 protein, apoptosisrelated caspase-3 appeared to be activated and apoptosis indicating poly-(ADP-ribose)polymerase followed to be cleaved, suggesting that downregulation of PC4 may trigger caspase-3-mediated apoptosis signaling pathway in A549 cells.
Although the pathogenesis of cancer is a complex process and many protein factors are involved in different stages, most cancer cells, however, share common characteristics, including uncontrolled growth and local tissue invasion or metastasis. Therefore, identification of universal type-independent cancer signatures is important to better understand cancer pathogenesis and ultimately improve early detection and therapeutics. Our discoveries that the active PC4 protein is overexpressed in lung cancer tissues and siRNA knocking down of PC4 resulted in a significant growth inhibition and apoptosis promotion suggest that PC4 may function as a potential target for lung cancer therapeutics. However, as PC4 is a nuclear protein, how to develop a convenient and sensitive detection method is challenging. Once the diagnostic tools are available, treatment of PC4-positive cancers with anti-PC4 reagents will be breakthrough in cancer therapy and an effective strategy for personalized medicine.
